ストックスクリーナーアプリを入手
150.17
0.81%
-1.23
前日終値:
$151.40
開ける：
$151.84
24時間の取引高:
1.64M
Relative Volume:
0.90
時価総額：
$286.54B
収益：
$54.66B
当期純損益:
$13.58B
株価収益率:
21.40
EPS:
7.0171
ネットキャッシュフロー:
$16.05B
1週間 パフォーマンス:
-1.21%
1か月 パフォーマンス:
+5.06%
6か月 パフォーマンス:
+15.16%
1年 パフォーマンス:
+33.39%
1日の値動き範囲:
$150.12
$152.03
1週間の範囲:
$149.96
$152.49
52週間の値動き範囲:
$112.34
$170.46
Novartis Ag Adr Stock (NVS) Company Profile
Compare NVS vs LLY, JNJ, ABBV, MRK, AZN
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
150.17 | 288.89B | 54.66B | 13.58B | 16.05B | 7.0171 |
LLY
Lilly Eli Co
|
1,105.00 | 1.00T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
225.33 | 555.59B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
217.72 | 386.27B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
118.72 | 296.11B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
185.67 | 287.42B | 60.48B | 10.40B | 8.05B | 3.3297 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-11 | アップグレード | Argus | Hold → Buy |
| 2026-01-27 | 開始されました | Citigroup | Buy |
| 2026-01-06 | アップグレード | Barclays | Underweight → Equal Weight |
| 2025-12-08 | アップグレード | JP Morgan | Neutral → Overweight |
| 2025-12-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-09-12 | ダウングレード | Goldman | Neutral → Sell |
| 2025-08-08 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2025-02-13 | ダウングレード | UBS | Buy → Neutral |
| 2025-02-12 | 開始されました | Morgan Stanley | Underweight |
| 2025-02-04 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-12-04 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2024-09-11 | ダウングレード | BofA Securities | Buy → Neutral |
| 2024-09-05 | ダウングレード | Goldman | Buy → Neutral |
| 2024-09-03 | ダウングレード | Jefferies | Buy → Hold |
| 2024-07-19 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2024-02-23 | 開始されました | BMO Capital Markets | Market Perform |
| 2024-01-23 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-01-16 | 再開されました | UBS | Buy |
| 2023-12-18 | ダウングレード | HSBC Securities | Buy → Hold |
| 2023-09-25 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-04-26 | アップグレード | Deutsche Bank | Hold → Buy |
| 2023-03-27 | アップグレード | Deutsche Bank | Sell → Hold |
| 2023-01-26 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-12-05 | アップグレード | Stifel | Hold → Buy |
| 2022-09-15 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2022-09-14 | ダウングレード | Berenberg | Buy → Hold |
| 2022-05-09 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2022-01-10 | 再開されました | Citigroup | Buy |
| 2021-12-14 | ダウングレード | Redburn | Buy → Neutral |
| 2021-12-06 | ダウングレード | Exane BNP Paribas | Outperform → Neutral |
| 2021-12-03 | ダウングレード | Bryan Garnier | Buy → Neutral |
| 2021-09-20 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2021-03-22 | 開始されました | Bernstein | Mkt Perform |
| 2021-03-10 | ダウングレード | Argus | Buy → Hold |
| 2021-02-01 | ダウングレード | Cowen | Outperform → Market Perform |
| 2021-01-15 | 開始されました | Deutsche Bank | Buy |
| 2020-09-29 | 開始されました | Berenberg | Buy |
| 2020-09-10 | アップグレード | UBS | Neutral → Buy |
| 2020-09-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-15 | アップグレード | Citigroup | Neutral → Buy |
| 2020-03-10 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2020-02-25 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-04-25 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-04-25 | アップグレード | Liberum | Hold → Buy |
| 2019-04-10 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2019-01-02 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-12-11 | 再開されました | Jefferies | Buy |
| 2018-10-09 | 開始されました | Guggenheim | Neutral |
| 2018-09-10 | アップグレード | BofA/Merrill | Underperform → Buy |
| 2018-05-29 | ダウングレード | HSBC Securities | Buy → Hold |
| 2018-05-25 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-01-25 | 繰り返されました | Leerink Partners | Outperform |
| 2017-12-06 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2017-07-26 | アップグレード | Morgan Stanley | Underweight → Overweight |
| 2017-07-05 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2017-03-09 | 開始されました | Liberum | Buy |
すべてを表示
Novartis Ag Adr (NVS) 最新ニュース
Novartis AG stock (CH0012005267): Pluvicto data keep focus on Swiss blue-chip pharma - AD HOC NEWS
Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer - GlobeNewswire Inc.
NVS News | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Novartis AG (ADR) stock (CH0012005267): steady trading ahead of next catalysts - AD HOC NEWS
Novartis AG stock (CH0012005267): shares little changed as investors digest Swiss pharma group’s s - AD HOC NEWS
Novartis AG stock (CH0012005267): focus on Sandoz spin-off and pipeline momentum - AD HOC NEWS
NVS Technical Analysis | Trend, Signals & Chart Patterns | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Novartis AG stock (CH0012005267): eyeing Sandoz spin-off and new drug approvals - AD HOC NEWS
Novartis AG stock (CH0012005267): new MS drug filing and Q1 momentum attract attention - AD HOC NEWS
Novartis AG stock (CH0012005267): Q1 update, Sandoz deconsolidation and pharma focus draw investor a - AD HOC NEWS
Novartis AG stock (CH0012005267): oncology focus, new drug readout and solid 2025 guidance in view - AD HOC NEWS
Novartis stock (CH0012005267): FDA progress and market focus - AD HOC NEWS
NVS Stock Price, Quote & Chart | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Novartis AG stock (CH0012005267): dividend profile and pipeline focus move into the spotlight - AD HOC NEWS
Novartis AG stock (CH0012005267): US expansion push with new Texas radioligand site - AD HOC NEWS
ETFs Investing in Novartis AG Sponsored ADR Stocks - TradingView
Novartis AG stock (CH0012005267): Recent 1.93% gain on SIX Swiss Exchange - AD HOC NEWS
Novartis AG stock (CH0012005267): NewEdge Wealth boosts stake amid mixed analyst views - AD HOC NEWS
NVSNovartis AG ADR Stock Price and Quote - Finviz
Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities - ChartMill
Trump's Drug Pricing Deals Could Lead To $529 Billion Savings For The Economy Over The Decade: Report - Sahm
Which Is a Better Investment, Novartis AG (ADR) or Pfizer Inc. Stock? - AAII.com
PTC Therapeutics Stock Sinks As Pivotal Data Fails To Calm Sellers - Sahm
Novartis AG Stock (CH0012005267): Q1 Revenue Miss Triggers Decline - AD HOC NEWS
Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility - ChartMill
Novartis CEO Flags Risks From Trump's MFN Drug Policy As Q1 Earnings Miss Estimates - Sahm
Earnings call transcript: Novartis Q1 2026 earnings miss forecasts, stock dips - Investing.com
Earnings call transcript: Novartis Q1 2026 earnings miss forecasts, stock dips By Investing.com - Investing.com Canada
Novartis (NYSE: NVS) Q1 2026 earnings dip as key drugs surge, Avidity deal closes - Stock Titan
Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed - ChartMill
Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria - ChartMill
Novartis AG (NVS) Stock Price, Trades & News - GuruFocus
Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA) - ChartMill
Dermatomycoses Market Report 2025-2035, Profiles of Prominent Players - GlobeNewswire Inc.
Peptide Drug Conjugate Market Landscape Report 2026: A $1.5 Billion Opportunity by 2031 - GlobeNewswire Inc.
Novartis AG stock (CH0012005267): Is its innovative drug pipeline strong enough to unlock new upside - AD HOC NEWS
Novartis AG (MEX:NVSN) Bonds - GuruFocus
Novartis AG (MEX:NVSN) Dividend - GuruFocus
Novartis AG stock (CH0012005267): Is its focused pharma strategy strong enough to unlock new upside? - AD HOC NEWS
Novartis AG (ADR) stock (CH0012005267): Why Google Discover changes matter more now - AD HOC NEWS
Novartis AG Stock Baskets | MEX:NVSN - GuruFocus
Novartis Ag Adr (NVS) 財務データ
収益
当期純利益
現金流量
EPS
0.18%
0.98%
大文字化:
|
ボリューム (24 時間):